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tion events were appropriately recorded in 8 events in 7 patients. There were 4452 false
arrhythmia automatic detections (mean 1.72 per patient per week) and 2801 alarms
(mean 0.26 per patient per week) to investigate electrode noise.
Conclusions: The incidence of ECG electrode signal disturbance with capacitive elec-
trodes was low without adhesives or electrolytic solutions, preventing any monitoring an
average of 0.7% of the time worn. Capacitive electrodes may be a new technology that
may be better suited than conventional electrodes in facilitating longer term event moni-
toring and automatic detection of arrhythmias.
1148-224 Abnormalities in Magnetocardiographic Atrial Signals in 
Patients With Focally Triggered Lone Atrial Fibrillation
Raija Koskinen, Heikki Väänänen, Mika Lehto, Juha Montonen, Lasse Lehtonen, Liisa-
Maria Voipio-Pulkki, Lauri Toivonen, Helsinki University Central Hospital, Helsinki, 
Finland
Subtle abnormalities in atrial signal could serve as markers of foci or substrate for atrial
fibrillation (AF). We applied high-resolution magnetocardiographic (MCG) mapping and
signal-averaged electrocardiography (SAECG) to analyze atrial depolarization waves in
17 patients (age 25-59 years) who had focally triggered and in 18 healthy controls (age
22-50 years). During sinus rhythm, a 33-channel MCG over anterior chest and orthogo-
nal SAECG were recorded in a magnetically shielded room. Data was averaged using
atrial wave template and high-pass filtered at 40 Hz. Onset and offset and root mean
square amplitudes (RMS) of atrial signal (P) were determined automatically. Variation in
atrial signal duration between channels was calculated as SD/P duration*100. In dupli-
cate tests, coefficient of variation of P duration was 3% in MCG and 5% in SAECG.
Results: P duration in MCG was similar in AF patients and controls, but variation in P
duration was marked in AF patients (table). Also amplitude of the last 60 ms (RMS60) but
not of the early part of atrial wave by MCG was reduced in AF patients. Similar determi-
nations by SAECG did not reveal statistically significant differences between AF patients
and controls.
Conclusion: Magnetocardiographic mapping can reveal abnormalities within the later part
of the atrial wave, where the left atrium is depolarized. These might indicate triggers or
perpetuators of focally initiated paroxysmal AF.
1148-225 Safe Scanning, but Frequent Artifacts Mimicking 
Tachycardia During Magnetic Resonance Imaging in 
Patients With Insertable Loop Recorders
J. Rod Gimbel, Jamal Zarghami, Christian Machado, Parkwest Hospital, Knoxville, TN, 
Providence Hospital, Southfield, MI
Background: Patients (pts) with implantable devices are generally not permitted to
undergo MRI because of potentially deleterious interactions. While over 200 pacemaker
pts and 6 ICD pts are reported to have undergone MRI, little has been reported regarding
the safety and effects of MRI scanning of pt with ILRs. We evaluated the safety of scan-
ning pts with ILRs and the output of the ILR after undergoing MRI.
Methods: Eight pts underwent a total of 9 MRI scanning events. All patients had Reveal
Plus ® (Medtronic, Minn, MN) ILRs. Seven cranial, one lumbar-spine, and one shoulder
MRI were performed. All of the MRIs were performed with the understanding that the
patient had an ILR. A physician was present for these scanning events. In each patient,
the ILR was cleared moments before the scan and the integrity of the signal and time
date stamp were verified. The devices were reinterrogated immediately after MRI in
seven instances and two days post MR scanning in one event. No patient was monitored
using EKG or pulse oximetry during MRI. Each patient was questioned post MRI regard-
ing any symptoms experienced during the scan.
Results: While no patient underwent monitoring during MRI, all patients denied experi-
encing any unusual cardiopulmonary or neurologic symptoms during MRI. Frequent wide
and narrow complex tachycardias appeared as artifacts as a result of ILR exposure to the
RF effects of MR scanning. Four of the 7 cranial scans produced an artifact mimicking
tachycardia as did the lumbar spine and shoulder scan. None of the ILRs showed dimin-
ished signal integrity, altered programmed parameters, inability to communicate or be
reprogrammed post MRI. No scanning artifacts compromising image interpretation were
noted by the radiologists.
Conclusion: In this series, MRI was performed in ILR patients without harm to the patient
or permanent damage to the ILR. MRI scanning of the Reveal appears safe. Artifact mim-
icking tachycardia was common, however, and must be excluded in any ILR patient
undergoing MRI to avoid mistakenly attributing a syncopal episode to the tachycardia
artifacts produced from RF present in the MR suite.
1148-266 Reverse Left Ventricular Remodeling by Carvedilol 
Reduces the Spatial Dispersion of QRS Duration in 
Patients With Chronic Heart Failure: A Prospective 
Placebo-Controlled Study
Takahisa Yamada, Tsuyoshi Shimonagata, Naoyuki Misaki, Mitsutoshi Asai, Nobuhiko 
Makino, Hidetaka Kioka, Shunsuke Tamaki, Masatake Fukunami, Osaka Prefectural 
General Hospital, Osaka, Japan
Background: Recent clinical trials have shown that carvedilol reduces the mortality in
patients with chronic heart failure (CHF), while amlodipine has no effect on the mortality.
However, the mechanism for these effects of carvedilol or amlodipine in patients with
CHF remained to be fully clarified from the viewpoint of spatial dispersion of QRS dura-
tion (S-QRSd), which we reported to be a prognostic marker of the mortality in CHF
patients.
Methods: We prospectively studied 123 CHF patients with radionuclide left ventricular
ejection fraction < 40% (29±7%), who were randomized to receive any of carvedilol
(n=44), amlodipine (n=42) or placebo (n=37) in a double-blinded fashion. Signal-aver-
aged ECG and echocardiography were repeated before and one year after the entry. Sig-
nal-averaged ECGs were recorded from the standard 12 leads and 10 extra-precordial
leads (two intercostal spaces upper and lower V1, V2 and V4-6). Spatial dispersion of
QRS duration (S-QRSd) was defined as the difference between the maximum and mini-
mum of filtered QRS duration in all of the leads.
Results: One year after the administration, carvedilol group had a significant decrease in
S-QRSd (25.6±8.4 to 22.2±7.2 ms, p<0.0001), while there was no significant change in
S-QRSd in amlodipine group (24.2±7.7 to 25.6±8.4 ms) but a significant increase in pla-
cebo group (24.1±8.6 to 27.7±8.3 ms, p=0.009). In carvedilol group, left ventricular end-
diastolic dimension (LVDd) significantly decreased (reverse remodeling) one year after
the administration (62.3±8.7 to 59.5±7.7 mm, p=0.005), while there was no change in
LVDd in amlodipine and placebo groups. There was a significant correlation between the
changes of S-QRSd and LVDd (r=0.336, p=0.0002).
Conclusion: Carvedilol reduces S-QRSd in relation to reverse left ventricular remodeling
in patients with CHF, while amlodipine has no effect on S-QRSd, which might result in the
different effects of these drugs on the mortality in patients with CHF.
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850-2 Value of Signal-Averaged ECG and Electrophysiological 
Testing in Identifying Arrhythmogenic Right Ventricle 
Dysplasia Patients Who Do Receive Implantable 
Cardioverter Defibrillator Therapy
Khurram Nasir, Darshan Dalal, Chandra Bomma, HariKrishna Tandri, Daniyal Ahmed, 
Ariel Roguin, Crsytal Tichnell, Cynthia James, Hugh Calkins, Johns Hopkins Medical 
Institutions, Baltimore, MD
Background: Implantable cardioverter defibrillator (ICD) placement is commonly recom-
mended for patients diagnosed with arrhytmogenic right ventricle dysplasia (ARVD).
Although this approach protects against even a low risk of sudden cardiac death, the life-
long implications of ICD in a young person are considerable. The aim of the study was to
determine if the results of SAECG and electrophysiology study (EPS) are of value in
identifying ARVD patients who are at particularly low risk of sudden cardiac death and
whom may not benefit from ICD placement.
Methods & Results: The study population consisted of 42 ARVD patients(52% males,
41±12 yrs) implanted with an ICD and followed for 20±19 months. Among these patients,
11 (26%) did not receive ICD therapies i.e. no shocks and/or anti-tachycardia pacing
[Therapy-Free group]. The mean filtered QRS duration (fQRSd) was 108±14 ms vs.
132±31 ms for the Therapy-Free vs. Therapy groups (p = 0.01). A higher proportion of
Therapy-Free compared to therapy group had fQRSd<110 ms (61% vs. 15%, p=0.003)
and a negative EPS (46% vs. 12%, p=0.01) respectively. In contrast, the therapy group
was more likely to have fQRSd of 110-120 ms (67% vs. 33%, p=0.001) and >120 ms
(92% vs. 7%, p=0.01). A combined algorithm of fQRS<110 ms and/or negative EPS was
100% predictive of a therapy free survival over a period of 67 months in these
patients.
Conclusions: A simple algorithm that combines fQRSd with outcome of EPS is
extremely predictive for identifying ICD therapy free survival in ARVD patients. 
Table
MCG variables AF patients Controls P-value
P duration (ms) 106+/-15 104+/-11 0.35
SD/P duration (%) 11.8+/-3.8 8.6+/-2.5 0.006
RMS60 (femtoT) 86+/-24 120+/-40 0.004
